English
Jubilant Pharmova Q2 Results
- BSE: 530019
- NSE: JUBLPHARMA
- ISIN: INE700A01033
- Sector: Biotechnology & Drugs
BSE
1,134.70
8.85 (0.79%)
8.85 (0.79%)Volume2.76 K
Updated: Fri 14 Nov, 2025 | 15:28:00
NSE
1,131.405.40 (0.48%)
5.40 (0.48%)Volume1.14 L
Updated: Fri 14 Nov, 2025 | 15:40:15
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q2 Results Highlights
- Total Income₹1,966.40 Cr.(12.22%)
- Operating Profit₹230.80 Cr.(25.57%)
- Profit After Tax₹120.30 Cr.(17.02%)
- Operating Margin11.74%(11.90%)
Note: Comparison is on YoY basis
Quarterly - Jubilant Pharmova Q2 Results
*All figures in crores except per share values
| Fiscal Period | Sep 25 | Jun 25 | QoQ Comp | Sep 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 1,735.60 | 1,709.20 | 1.54% | 1,568.50 | 10.65% |
| Depreciation/ Amortization | 104.80 | 98.10 | 6.83% | 91.40 | 14.66% |
| Operating Income | 230.80 | 191.50 | 20.52% | 183.80 | 25.57% |
| Net Income | 120.30 | 102.90 | 16.91% | 102.80 | 17.02% |
| Other Operating Expenses Total | 392.30 | 401.80 | -2.36% | 343.80 | 14.11% |
| Net Income Before Taxes | 190.30 | 154.40 | 23.25% | 144.40 | 31.79% |
| Total Revenue | 1,966.40 | 1,900.70 | 3.46% | 1,752.30 | 12.22% |
| Selling/ General/ Admin Expenses Total | 636.20 | 591.10 | 7.63% | 564.30 | 12.74% |
| Diluted Normalized EPS | 7.80 | 6.47 | 20.56% | 7.09 | 9.96% |